Back to Atlas
BSemi-durableStandard research/education caution
CMP-0635
Research chemical/reference listing
Glepaglutide
Immune modulation
Immune balance, inflammation, or resilience support
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Immune / inflammatory modulator
- Primary mechanism
- Immune or inflammatory pathway modulation
- Primary market use
- Immune modulation
Pharmacology
- Molecular weight (Da)
- 4376.06
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~1–7 days (half-life-extended peptide class estimate)
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 7 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease.